Telomere Therapeutics

BiotechnologySeedBarcelona, Spain

Latest round

Seed

Last raised

Dec 2020

Total raised

$1.8M

Investors

1

About Telomere Therapeutics

Founded in 2020 and based in Barcelona, Spain, Telomere Therapeutics operates as a biotechnology company that develops telomerase gene therapy to treat pulmonary fibrosis and renal fibrosis, a lung and kidney disease.

Who invested in Telomere Therapeutics

1 investor across 1 round

See all investors in Telomere Therapeutics

Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.

Funding rounds

  1. Seed

    Dec 1, 2020

    Amount

    $1.8M

    Investors

    Locked

Questions about Telomere Therapeutics

Who invested in Telomere Therapeutics?

Telomere Therapeutics has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.

How much funding has Telomere Therapeutics raised?

Telomere Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.

When did Telomere Therapeutics last raise money?

Telomere Therapeutics's most recent round on record is a Seed, in Dec 2020.

What does Telomere Therapeutics do?

Founded in 2020 and based in Barcelona, Spain, Telomere Therapeutics operates as a biotechnology company that develops telomerase gene therapy to treat pulmonary fibrosis and renal fibrosis, a lung and kidney disease.

Where is Telomere Therapeutics headquartered?

Telomere Therapeutics is headquartered in Barcelona, Spain.

Which VCs invest in companies like Telomere Therapeutics?

Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at Telomere Therapeutics's stage. Their profiles are linked below.

Raising like Telomere Therapeutics? Find the right VCs.

Capital Atlas matches your startup to active investors by stage, sector and region.

Free to start. Upgrade when you're ready to reach out.